• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Immunogenicity and safety of Mebella ™ vaccine developed by Human Biologicals Institute in a Phase II/III, randomized, multicentric, non-inferiority study
CONCLUSION: It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years of age. Clinical Trial Registry of India Identifier: CTRI/2020/07/026930.PMID:37659893 | DOI:10.1016/j.vaccine.2023.08.065
Source: Vaccine - September 2, 2023 Category: Allergy & Immunology Authors: Sai Krishna Susarla Rahul Jahagirdar Kheya Ghosh Uttam S Srikanth Bhatt S Prashanth Vasudev Rajapantula M Satish B C Rajashakar G Sandhya L Rajendra Devi Prasad Sahoo Anand Kumar Kanakasapapathy Source Type: research

Adverse events following immunization: Findings from 2017/2018 measles vaccination campaign, Nigeria AEFI reporting in 2017/2018 measles vaccination campaign
CONCLUSION: Adequate AEFI reporting, Investigation and management remains important in managing the risk of a disruption of mass campaigns. The deployment of supervisors during campaign may play an important role in improving the identification and reporting of suspected AEFI. Further inquiries about AEFIs during the post campaign coverage evaluation also played a role in improving AEFI reporting and documentation. The real-time, on the spot, follow up by the national operations team helped with decision making and intervention including AEFI investigations and assessments.PMID:33714655 | DOI:10.1016/j.vaccine.2021.02.067
Source: Vaccine - March 14, 2021 Category: Allergy & Immunology Authors: Ene Gbenewei Terna Nomhwange Lydia Taiwo Isiaka Ayodeji Kabir Yusuf Anne E Jean Baptiste Peter Nsubuga Fiona Braka Joseph Oteri Faisal Shuaib Source Type: research

Reply to Lee et al.'s letter to the editor pertaining to our publication entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review".
PMID: 30348362 [PubMed - in process]
Source: Vaccine - October 25, 2018 Category: Allergy & Immunology Authors: Willame C, Lin L, Vetter V, Baril L, Praet N Tags: Vaccine Source Type: research

To the editor: Response to Willame, et al., published in Vaccine 35 (2017) 5551-5558, entitled "Pain caused by measles, mumps, and rubella vaccines: A systematic literature review".
PMID: 30348361 [PubMed - in process]
Source: Vaccine - October 25, 2018 Category: Allergy & Immunology Authors: Lee AW, Saldutti LP, Wolfson LJ, Stek JE, Kuter BJ Tags: Vaccine Source Type: research

Adverse effects of single-component measles vaccine in school children.
In conclusion, single-component measles vaccine was found to be safe in previously MMR vaccinated children in short term and long term effects may be need to be clarified by further studies. PMID: 29128384 [PubMed - as supplied by publisher]
Source: Vaccine - November 8, 2017 Category: Allergy & Immunology Authors: Tosun S, Olut AI, Tansug N Tags: Vaccine Source Type: research

Analysis of safety data in children after receiving two doses of ProQuad® (MMRV).
CONCLUSIONS: Administration of two doses of MMRV has an acceptable safety profile in children 12 to 23 months of age. There is a small increase in the risk of febrile seizures following the first dose of MMRV as compared to the component vaccines, but the risk for any individual child is very small. PMID: 25219563 [PubMed - as supplied by publisher]
Source: Vaccine - September 11, 2014 Category: Allergy & Immunology Authors: Klopfer SO, Stek JE, Petrecz M, Reisinger KS, Black SB, Goveia MG, Nicholson O, Gardner JL, Grosso AD, Brown ML, Kuter BJ, Schödel FP Tags: Vaccine Source Type: research